Fuenzalida-Palacios. INSTITUTE OF PUBLIC HEALTH (Fuenzalida and Palacios, 1955)
This vaccine is a suspension of fixed rabies virus grown in suckling mouse brain from 1 to 3 days age and inactivated with ultraviolet light. 
Each 2 ml dose of vaccine should have an activity equal to or greater than 2.5 IU. dose contains nervous tissue of suckling mouse brain infected with fixed rabies virus: 40% of CVS (Challenge Virus Standard), 40% and 20% strain 51 strain 91. Phenol and thimerosal in amounts no greater than 2 mg and 0.22 mg respectively.
Administration. Preventive use: dose of 2 ml intramuscularly, to be applied to healthy dogs of any size and preferably to dogs over 4 months old.
Precautions: Shake the vial before removing each dose of vaccine; keep refrigerated between 2 and 8 ° C. Do not freeze
is currently being prepared in Mexico: Institute of Hygiene of the Ministry of Health. And in Argentina, Instituto de Zoonosis Luis Pasteur. In Chile, there has been preparing
2003 (Favier et al, 2004). References
E. Fuenzalida, R. Palacios. 1955. An improved method for the preparation of rabies vaccine. Bull Inst Bact. Chile 1 (13): 3 - 10.
Favi M., V. Yung, O. Roos, L. Rodriguez, R. Trujillo, A. Acevedo. 2004. Evaluation of the immunogenicity of rabies vaccine Fuenzalida-Palacios (CRL) and cell culture rabies vaccine (Verorab ®) in people with pre-exposure treatment. Rev. Phys. Chile. 132 (1): 41 - 46.
0 comments:
Post a Comment